Central Pacific Bank Trust Division Has $70,000 Position in Hologic, Inc. (NASDAQ:HOLX)

Central Pacific Bank Trust Division cut its holdings in shares of Hologic, Inc. (NASDAQ:HOLX) by 15.8% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 854 shares of the medical equipment provider’s stock after selling 160 shares during the period. Central Pacific Bank Trust Division’s holdings in Hologic were worth $70,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in HOLX. NEOS Investment Management LLC acquired a new stake in Hologic during the 4th quarter worth approximately $233,000. Goldman Sachs Group Inc. boosted its position in Hologic by 5.7% during the 4th quarter. Goldman Sachs Group Inc. now owns 1,314,278 shares of the medical equipment provider’s stock worth $93,905,000 after buying an additional 71,222 shares during the period. Tower Research Capital LLC TRC boosted its position in Hologic by 282.2% during the 4th quarter. Tower Research Capital LLC TRC now owns 48,234 shares of the medical equipment provider’s stock worth $3,446,000 after buying an additional 35,614 shares during the period. Oppenheimer & Co. Inc. raised its holdings in Hologic by 32.1% during the 4th quarter. Oppenheimer & Co. Inc. now owns 19,025 shares of the medical equipment provider’s stock worth $1,359,000 after purchasing an additional 4,625 shares during the last quarter. Finally, 1832 Asset Management L.P. raised its holdings in Hologic by 13.6% during the 4th quarter. 1832 Asset Management L.P. now owns 25,820 shares of the medical equipment provider’s stock worth $1,845,000 after purchasing an additional 3,091 shares during the last quarter. 94.73% of the stock is currently owned by institutional investors and hedge funds.

Hologic Stock Up 1.3 %

HOLX stock traded up $1.02 during midday trading on Friday, reaching $80.24. 1,245,584 shares of the company’s stock traded hands, compared to its average volume of 1,600,160. The company has a market cap of $18.73 billion, a price-to-earnings ratio of 40.94, a P/E/G ratio of 2.58 and a beta of 0.98. The firm’s fifty day moving average price is $81.24 and its 200-day moving average price is $77.39. The company has a quick ratio of 3.32, a current ratio of 3.99 and a debt-to-equity ratio of 0.51. Hologic, Inc. has a 52 week low of $64.02 and a 52 week high of $84.67.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings results on Monday, July 29th. The medical equipment provider reported $1.06 EPS for the quarter, beating analysts’ consensus estimates of $1.02 by $0.04. The business had revenue of $1.01 billion during the quarter, compared to analyst estimates of $1 billion. Hologic had a net margin of 17.59% and a return on equity of 19.53%. Hologic’s quarterly revenue was up 2.7% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.93 EPS. As a group, sell-side analysts forecast that Hologic, Inc. will post 4.09 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms have issued reports on HOLX. Stephens restated an “overweight” rating and set a $92.00 price target on shares of Hologic in a report on Tuesday, July 30th. Evercore ISI raised their price target on shares of Hologic from $78.00 to $82.00 and gave the stock an “in-line” rating in a report on Tuesday. StockNews.com lowered shares of Hologic from a “strong-buy” rating to a “buy” rating in a report on Friday, September 27th. Needham & Company LLC restated a “buy” rating and set a $90.00 price target on shares of Hologic in a report on Tuesday, September 17th. Finally, Mizuho raised their price target on shares of Hologic from $85.00 to $90.00 and gave the stock an “outperform” rating in a report on Friday. Five analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $87.27.

Insider Buying and Selling at Hologic

In other Hologic news, insider Benjamin Jordan Cohn sold 5,093 shares of Hologic stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $81.99, for a total transaction of $417,575.07. Following the transaction, the insider now directly owns 10,476 shares of the company’s stock, valued at $858,927.24. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, insider Benjamin Jordan Cohn sold 5,093 shares of the business’s stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $81.99, for a total value of $417,575.07. Following the transaction, the insider now directly owns 10,476 shares of the company’s stock, valued at approximately $858,927.24. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Brandon Schnittker sold 476 shares of the business’s stock in a transaction dated Tuesday, August 6th. The stock was sold at an average price of $83.11, for a total transaction of $39,560.36. Following the completion of the transaction, the insider now directly owns 3,735 shares in the company, valued at $310,415.85. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 18,280 shares of company stock worth $1,469,973. 1.75% of the stock is owned by corporate insiders.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.